Bio-Path (NASDAQ:BPTH) Downgraded by Zacks Investment Research to Hold

Bio-Path} stock has undergone multiple analysts rating changes in the recent past.  Bio-Path Downgraded by Zacks Investment Research on 10/18/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More Bio-Path (NASDAQ:BPTH) Downgraded by Zacks Investment Research to Hold